Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
出版年份 2023 全文链接
标题
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2023-02-04
DOI
10.1200/jco.22.01450
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- (2022) Vicky Makker et al. NEW ENGLAND JOURNAL OF MEDICINE
- RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.
- (2022) Li Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
- (2022) Xiangrui Meng et al. Lancet Gastroenterology & Hepatology
- Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
- (2021) Feng-Hua Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study
- (2021) Luo Huang et al. ORAL ONCOLOGY
- Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
- (2021) Kuimin Mei et al. Journal for ImmunoTherapy of Cancer
- 858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
- (2021) A.T. Chan et al. ANNALS OF ONCOLOGY
- Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single‐arm, prospective phase 2 study
- (2021) Xiaolan Ruan et al. CANCER
- Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
- (2021) Chung-Han Lee et al. LANCET ONCOLOGY
- Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
- (2021) Yunpeng Yang et al. LANCET ONCOLOGY
- Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
- (2021) Hai-Qiang Mai et al. NATURE MEDICINE
- Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
- (2021) Hongyan Cheng et al. LANCET ONCOLOGY
- Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
- (2020) Ling Li et al. INVESTIGATIONAL NEW DRUGS
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma
- (2020) Liya Zhou et al. Drug Design Development and Therapy
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
- (2020) Chunyan Lan et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma
- (2019) Jun Jin et al. MEDICINE
- Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer
- (2019) Sha Zhao et al. Cancer Immunology Research
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Nasopharyngeal carcinoma
- (2019) Yu-Pei Chen et al. LANCET
- Tumor Vasculatures: A New Target for Cancer Immunotherapy
- (2019) Zhigang Liu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Management of locally recurrent nasopharyngeal carcinoma
- (2019) Anne W.M. Lee et al. CANCER TREATMENT REVIEWS
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
- (2018) Brigette B.Y. Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy
- (2018) You Quan Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Proposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosis
- (2017) Qi Yang et al. ORAL ONCOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
- (2016) Li Zhang et al. LANCET
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Clinical findings and imaging features of 67 nasopharyngeal carcinoma patients with postradiation nasopharyngeal necrosis
- (2013) Ming-Yuan Chen et al. Chinese Journal of Cancer
- Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma†
- (2012) C. Xue et al. ANNALS OF ONCOLOGY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation
- (2011) E. P. Hui et al. ANNALS OF ONCOLOGY
- A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
- (2011) Wan-Teck Lim et al. CLINICAL CANCER RESEARCH
- The prevalence and prevention of nasopharyngeal carcinoma in China
- (2011) Su-Mei Cao et al. Chinese Journal of Cancer
- New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
- (2010) Lance Cowey OncoTargets and Therapy
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now